

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
MILLER A B	UFHSCJ/MEDICINE	SANOFI-SYNTHELABO RESEARCH US		A MULTCTR, RNDIZED, PLA-CTRLLD, DBLE-BLIND TRIAL TO EVALUATE THE VASOPRESSIN V2 RECEPTOR ANTAGONIST	09/01/2001	06/11/2004	\$11,400.00	12/05/2003
MASOOD S	UFHSCJ/PATHOLOGY	NORTHWESTERN UNIVERSITY	F027	SURRIGATE ENDPOINTS IN PREVENTION STUDIES & DUCTAL LAVAGE	09/01/2003	08/31/2004	\$8,610.00	12/22/2003
OSTROV D A	PATHOLOGY & LABORATORY MED	CURE AUTISM NOW (LACAN)		PREVENTION OF AUTISM SPECTRUM DISORDERS BY MODULATING T-CELL RESPONSIVENESS	02/02/2004	01/30/2006	\$60,000.00	12/31/2003
PAPKE R L	PHARMACOLOGY & THERAPEUTICS	UNIV OF KENTUCKY RESEARCH FDTN	F027	DEVELOPMENT OF NOVEL TREATMENTS FOR NICOTINE ADDICTION (SUB TO UNIV OF KENTUCKY)	09/30/2003	06/30/2008	\$96,080.00	12/22/2003
FLETCHER B S	PHARMACOLOGY & THERAPEUTICS	AM HEART ASSOCIATION		TRANSDUCER MEDIATED GENE THERAPY OF HYPERTENSION	01/01/2004	12/31/2006	\$65,000.00	12/31/2003
REISS J G	INST FOR CHILD HEALTH POLICY	FL DEV DISABILITIES COUNCIL	F059	PROMOTING HEALTH CARE TRANSITION OF YOUTH & YOUNG ADULTS W/ DEVELOPMENTAL DISABILITIES	09/10/2003	09/30/2004	\$54,438.00	12/02/2003
SHEA B F	CANCER CENTER	MERCK & COMPANY INC		A RNDMZD DBL-BL PRELIM-GROUP STDY CONDUCTED UNDER IN-HOUSE BLINDING CONDITIONS TO DETERMINE THE EFFICACY &	10/01/2002	04/30/2004	\$11,600.00	12/24/2003
FORSMARK C E	MEDICINE	ASTRAZENECA		MULTI-CTR RNDMZD DBL-BL PLCB-CNTRL EFFIC STDY COMPAR 4 WKS TX W/ESOMEPRZOLE COMPARED PLCB IN PTS	04/24/2003	04/24/2004	\$1,800.00	12/23/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
DRISCOLL D J	PEDIATRICS	BAYLOR UNIVERSITY	F027	RARE DISEASE CRC FOR NEW THERAPIES AND NEW DIAGNOSTICS	09/30/2003	07/31/2004	\$135,038.00	12/05/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
CHALAM K V	UFHSCJ/MEDICINE	IMMUSOL INC		A SAFETY AND EFFICACY ASSESSMENT OF CHIMERIC RIBOZYME TO PCNA TO PREVENT RECURRENCE OF PROLIFERATIVE	08/01/2003	07/30/2004	\$3,300.00	12/17/2003
ILFELD B M	ANESTHESIOLOGY	ASTRAZENECA		OPTIMAL LOCAL ANESTHETIC DOSING REGIMEN FOR POSTOPERATIVE PERINEURAL INFUSIONS	09/04/2003	09/03/2004	\$2,500.00	12/03/2003
GUTHRIE T H	UFHSCJ/MEDICINE	BRISTOL-MYERS SQUIBB COMPANY		PHASE III,...IRINOTECAN AND CETUXIMAB VS. IRINOTECAN AS 2ND LINE TMT IN PATIENTS WITH MET. EGFR+ COLON CA	09/20/2003	09/19/2004	\$8,000.00	12/29/2003
LONG J R	BIOCHEMISTRY & MOLECULAR BIO	AM HEART ASSOCIATION		SOLID STATE NMR STUDIES OF A MEMBRANE-ASSOCIATE PEPTIDE: THE ROLE OF MEMBRANE COMPOSITION ON ION CHANNEL	01/01/2004	12/31/2007	\$65,000.00	12/11/2003
STETSON JR R A	PSYCHIATRY	ABBOTT LABORATORIES		A RMDIZED...OF DEPAKOTE ER PLUS AN ATYPICAL ANTIPSYCHOTIC VS AN ATYPICAL ANTIPSYCHOTIC	08/04/2003	08/03/2005	\$23,146.26	12/30/2003
LAMBIASE L R	UFHSCJ/MEDICINE	ICON CLINICAL RESEARCH INC		SEVERE DIARRHEA_PREDOMINANT IBS IN FEMALE PATIENTS	09/02/2003	09/01/2004	\$500.00	12/05/2003
BUSSING R	PSYCHIATRY	SHIRE PHARMACEUTICAL DEV		A PHASE III, MLT-CNTR, 18-MO, OPEN- LABEL SAFETY,TOLERABILITY AND EFFICACY STUDY OF ADDERALL XR	08/14/2003	08/14/2006	\$5,000.00	12/01/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
STAUD R	MEDICINE	AM FIBROMYALGIA SYNDROME ASSOC		THE ROLE OF INFLAMMATION FOR PAIN IN PATIENTS WITH FIBROMYALGIA SYNDROME	01/01/2004	06/30/2005	\$75,000.00	12/01/2003

PI	DEPARTMENT	FUNDING AGENCY	SUB TO UF CODE	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
JOHNSON R J	MEDICINE	BAYLOR UNIVERSITY	F027	RENAL INFLAMMATION: MECHANISMS AND CONSEQUENCES: PROJECT 1 URIC ACID IN SYSTEMIC AND RENAL	09/01/2003	04/30/2004	\$67,860.00	12/01/2003
MELKER R J	ANESTHESIOLOGY	BAYER GROUP		EVALUATION OF ENVIRONMENTAL EFFECT OF GLUCOSE TEST STRIP ACCURACY	09/22/2003	09/21/2004	\$14,625.00	12/02/2003
SCHMALFUSS I M	RADIOLOGY	BRACCO DIAGNOSTICS INC		PHASE IIIB, DOUBLE-BLIND, MULTICENTER, RANDOMIZED CROSSOVER STUDY TO COMPARE 0.10 MMOL/KG OF MULTI-HANCE	10/01/2003	10/01/2004	\$5,625.00	12/31/2003
BICHER G S	CTR CLINICAL TRIALS RES (CCTR)	ABBOTT LABORATORIES		A PHASE 1 SINGLE AND MULTIPLE DOSE STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ZEMPLAR	09/18/2003	09/18/2004	\$31,749.38	12/08/2003
SHENKMAN E A	INST FOR CHILD HEALTH POLICY	DEPT OF HEALTH		EVALUATION OF THE CMS WAIT LIST, FALL 2003	10/15/2003	11/15/2003	\$21,645.00	12/10/2003
MURPHY T	PSYCHIATRY	BRISTOL-MYERS SQUIBB COMPANY		ARIPRAZOLE IN THE TREATMENT OF TOURETTE'S SYNDROME	10/30/2003	10/02/2004	\$24,500.00	12/09/2003
BRADLEY PETTIGREW K	PEDIATRICS	TUFTS HEALTH CARE INSTITUTE	F033	ON-LINE LEARNING PROGRAM IN SYSTEMS-BASED CARE AND PRACTICE- BASED LEARNING AND IMPROVEMENT: A CURRICULUM	09/01/2002	08/31/2004	\$6,500.00	12/10/2003
JOHNSON R J	MEDICINE	JUVENILE DIABETES FOUNDATION		COULD THE UNCOUPLING OF NO AND VEGF PRODUCTION BE RESPONSIBL FOR THE DEVELOPMENT OF DIABETIC	09/01/2003	12/31/2003	\$20,000.00	12/02/2003